BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 393441)

  • 1. Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment.
    Zielinski C; Pehamberger H; Endler AT; Knapp W
    Clin Exp Immunol; 1979 Oct; 38(1):92-8. PubMed ID: 393441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B; Wätzig V; Knöll B
    Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BCG-induced production of a factor inhibiting macrophage migration and growth of melanoma B16].
    Gankovskaia LV; Pyl'nova TI; Sokolova EV; Koval'chuk LV
    Biull Eksp Biol Med; 1980 Sep; 90(9):346-8. PubMed ID: 7000202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cell-mediated immunity in patients with malignant melanoma.
    Fixa B; Komárková O; Kraus Z; Simková H
    Neoplasma; 1978; 25(3):353-7. PubMed ID: 683378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological changes in cancer patients receiving BCG.
    Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
    Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts in the management of malignant melanoma.
    Lichtenfeld JL
    Am J Med Sci; 1976; 272(2):185-95. PubMed ID: 1008080
    [No Abstract]   [Full Text] [Related]  

  • 8. [Unspecific immunological investigations in patients with malignant melanoma (author's transl)].
    Knopf B; Wätzig V
    Dermatol Monatsschr; 1982 Jan; 168(1):24-33. PubMed ID: 7044849
    [No Abstract]   [Full Text] [Related]  

  • 9. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of leukocyte migration by soluble tumor extracts in human malignant melanoma.
    Lapińska M; Jassem J; Kondrat W; Jaśkiewicz J
    Neoplasma; 1980; 27(1):37-42. PubMed ID: 6154899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
    Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [BCG-treatment of malignant melanoma].
    Borberg H
    Internist (Berl); 1975 Oct; 16(10):482-5. PubMed ID: 1107254
    [No Abstract]   [Full Text] [Related]  

  • 14. Progress of immunotherapy in the treatment of malignant melanoma.
    Ariyan S
    Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of leukocyte migration inhibition test in studying allergy to rifampicin].
    Janicka G
    Pol Tyg Lek; 1976 Jan; 31(1):13-4. PubMed ID: 765975
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of an immunosuppressive factor in pregnancy serum.
    Stimson WH; Blackstock JC
    Obstet Gynecol; 1976 Sep; 48(3):305-11. PubMed ID: 781575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopathologic changes in patients with cutaneous malignant melanoma following intratumoral inoculation BCG: correlation with cell-mediated immunity.
    Lieberman R; Epstein W; Fudenberg HH
    Int J Cancer; 1974 Sep; 14(3):401-16. PubMed ID: 4617711
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.